[Tacrine: progress in treatment of Alzheimer's disease?].
The cholinesterase inhibitor tacrine exerts a marked therapeutic effect only at a dose which is not tolerated by many patients because of the gastrointestinal side effects and hepatotoxicity of the drug. In patients who tolerate a high dose of tacrine the mean increase in cognitive abilities is roughly equivalent to the decline which occurs within 1 year in an untreated group. At a high dose tacrine may also temporarily delay the progression of symptoms of Alzheimer's disease. Only a minority of patients with mild to moderate Alzheimer's disease can be treated with tacrine. For them, however, tacrine is the most promising treatment option presently available.
Kurz
A
A
Psychiatrische Klinik, Technischen Universität, München.
Marquard
R
R
Mösch
D
D
D000368:Aged; D000544:Alzheimer Disease / Q000145:classification / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008134:Long-Term Care; D009483:Neuropsychological Tests; D013619:Tacrine / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D013619:Tacrine
Tacrin: Ein Fortschritt in der Behandlung der Alzheimer-Krankheit?